Catheter Precision Inc Dossier - Source-backed chat

Catheter Precision Inc

VTAKNYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.15Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $548.6K

Enterprise Value $3M

Shares Outstanding 3.6M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Catheter Precision, Inc. (VTAK) is undergoing a radical corporate transformation, pivoting from a commercial-stage cardiac electrophysiology medical device developer to a pure-play regional private aviation charter operator. Following its late 2025/early 2026 acquisition of Fly Flyte, Inc., the company has formally engaged a strategic advisor to divest its FDA-cleared and CE-marked cardiac assets (VIVO and LockeT). While Q1 2026 results demonstrated strong initial revenue traction (up 200% YoY to $432,000) driven by the new aviation segment, the company faces severe liquidity constraints, a substantial accumulated deficit of $311.2 million, and ongoing going-concern risks. A 'Hold' recommendation is advised until the legacy medical assets are successfully monetized and the aviation business establishes a clear path to operational self-sustainability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company struggles to find a buyer for its cardiac assets, leading to continued cash burn from legacy operations. Flyte's expansion is hampered by high fuel costs, pilot shortages, or regulatory delays, forcing the company to execute highly dilutive equity financings or face restructuring due to its going-concern status.

Base CaseCentral scenario

The company successfully divests its cardiac electrophysiology business to a larger, well-capitalized medical technology acquirer, generating non-dilutive cash to fund the expansion of its Flyte aviation platform. Flyte capitalizes on high-demand Northeast short-haul routes and successfully expands into regional international markets (e.g., Toronto, Bahamas), driving steady revenue growth and narrowing operating losses.

Bull CaseUpside scenario

Successful commercial scaling of the Flyte regional aviation platform alongside global adoption of VIVO and LockeT medical devices, driving rapid revenue growth and path to profitability.

Scenarios reflect our research view at the research date.

Key Investment Merits

Successful pivot to a high-growth, technology-enabled regional air mobility market (Flyte) with immediate revenue contribution ($184,000 in Q1 2026).
Potential for non-dilutive capital injection through the formal sale of FDA-cleared and CE-marked cardiac mapping (VIVO) and wound closure (LockeT) technologies.
Restructured balance sheet with the termination of the dilutive ATM equity program and up to $88 million in strategic institutional financing secured.

Key Investment Risks

Substantial doubt exists regarding the company's ability to continue as a going concern, with only $0.4 million in cash as of March 31, 2026.
Execution and integration risks associated with managing two entirely unrelated business segments during the transition phase.
High customer concentration risk and potential equity dilution from outstanding warrants and preferred stock series.

Thesis Invalidation Triggers

Termination of the strategic marketing process for the cardiac electrophysiology business without a sale.
Inability to secure additional working capital within the next 12 months, leading to technical default or insolvency.
A severe downturn in regional private aviation demand or grounding of the Cirrus Vision Jet fleet.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.